Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹1,870.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹261.81B
Enterprise Value₹281.75B
Total Cash (Recent Filing)₹9.30B
Total Debt (Recent Filing)₹24.56B
Price to Earnings (P/E)28.7
Beta1.50
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Return To Profitability & Revenue RecoveryA return to net profitability alongside ~12% top-line growth signals the company has stabilized core sales and can generate earnings again. Over 2–6 months this supports reinvestment in products, reduces insolvency risk, and improves ability to service obligations if earnings persistence continues.
Improved Balance-sheet CushioningA larger equity base and broadly stable debt levels reduce leverage pressure and provide capital buffers for capex, regulatory compliance and working-capital needs. This structural improvement supports funding flexibility and resilience versus prior weaker years if earnings remain positive.
Diversified Pharma Business ModelMultiple durable revenue streams—branded formulations, API sales and contract manufacturing—spread commercial and regulatory risk and allow shifting mix toward higher-value regulated-market work over time. This diversification supports steadier cash generation across cycles.
Bears Say
Volatile Cash GenerationUneven conversion of earnings into cash—recent positive OCF but very modest and falling FCF—implies limited internal funding for growth or debt reduction. Over months this raises refinancing and investment risk, and restricts ability to consistently fund regulatory or capacity investments.
Multi-year Profitability InconsistencyHistoric swings between profit and loss indicate weak earnings predictability and margin stability. This undermines long-term planning and capital allocation, increases the chance of earnings reversals, and makes sustained investment in R&D and compliance more uncertain.
Residual Balance-sheet VulnerabilityAlthough equity increased, prior multi-year losses and negative ROE episodes could erode buffers if profitability lapses recur. Given pharma's capital and regulatory spending needs, renewed earnings weakness would quickly stress liquidity and limit strategic optionality.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹1870.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹261.81B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Aug 07, 2026 which is in 78 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on May 04, 2026. The company reported ₹10.23 earnings per share for the quarter, beating the consensus estimate of N/A by ₹10.23.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹10.23 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.216%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―